{"gene":"APOBEC1","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":1995,"finding":"APOBEC1 (apobec-1) has distinct functional domains: zinc-coordinating residues (His61, Cys93, Cys96) and catalytic Glu63 are required for both cytidine deaminase activity and apoB RNA editing; the leucine-rich region (LRR) is required for RNA editing but not cytidine deaminase activity; His61 is required for RNA binding. Dominant negative mutants (Glu63→Gln, His61→Arg) reduce endogenous editing when overexpressed.","method":"Site-directed mutagenesis of GST-fusion APOBEC1, in vitro cytidine deaminase assay, apoB RNA editing assay, UV cross-linking RNA binding assay, transfection into McA 7777 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution + mutagenesis of multiple residues with in vitro assays and in vivo functional validation, multiple orthogonal methods","pmids":["7782343"],"is_preprint":false},{"year":1995,"finding":"Recombinant APOBEC1 binds apoB RNA with high specificity via UV cross-linking and EMSA; binding is competed by poly(U) and poly(A,U) but not poly(A); RNA binding specificity for editing is distinct from mooring-sequence dependence.","method":"UV cross-linking, electrophoretic mobility shift assay (EMSA), RNA competition assays with recombinant GST/APOBEC-1","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with multiple orthogonal binding assays (UV cross-linking + EMSA), rigorous competition controls","pmids":["7782342"],"is_preprint":false},{"year":1996,"finding":"Targeted disruption of mouse apobec-1 gene abolishes all apoB mRNA editing and eliminates apoB48 in serum, demonstrating that Apobec-1 is the essential catalytic component with no functional gene duplication.","method":"Gene targeting/knockout mice, RNA analysis of apoB mRNA editing, serum apoB48 Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with defined molecular phenotype, replicated in a second independent knockout study (PMID:8824235)","pmids":["8621694","8824235"],"is_preprint":false},{"year":1996,"finding":"APOBEC-1 overexpression in stable hepatoma cell lines causes promiscuous editing of cytidines 5' of the mooring sequence in addition to the canonical site, and this hyperediting is mooring-sequence dependent and proportional to APOBEC-1 levels.","method":"Stable cell lines overexpressing APOBEC-1, apoB RNA editing assay, sequencing of editing products","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based loss/gain of function with direct editing readout, single lab","pmids":["8621694"],"is_preprint":false},{"year":1996,"finding":"APOBEC-1 requires auxiliary proteins (complementing activity) for apoB mRNA editing in vitro; recombinant APOBEC-1 immobilized on beads can deplete complementing activity from extracts and reconstitute editing, and the complementing protein (65 kDa) interacts directly with APOBEC-1 independently of apoB mRNA. The C-terminal 59 amino acids of APOBEC-1 are not required for this interaction.","method":"APOBEC-1 affinity chromatography, reconstitution in vitro editing assay, size exclusion chromatography, glycerol gradient sedimentation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with affinity chromatography and depletion/rescue experiments, multiple biochemical methods","pmids":["8910449"],"is_preprint":false},{"year":1997,"finding":"ABBP-1, a novel RNA-binding protein identified by yeast two-hybrid using apobec-1 as bait, binds apobec-1 via its glycine-rich C-terminal domain, binds apoB mRNA around the editing site, and is required for apoB mRNA editing (immunodepletion abolishes editing; antisense knockdown reduces editing).","method":"Yeast two-hybrid, deletion mapping, UV cross-linking to apoB mRNA, immunodepletion from active extracts, antisense knockdown in HepG2 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus in vitro immunodepletion and cell-based knockdown, single lab","pmids":["8999813"],"is_preprint":false},{"year":1997,"finding":"A dominant negative APOBEC-1 mutant (mu1: H61K/C93S/C96S) retains dimerization capacity with wild-type APOBEC-1 and inhibits its editing activity; two other inactive mutants with poor dimerization fail to inhibit, demonstrating that active APOBEC-1 functions as a homodimer and dimerization is required for dominant negative inhibition.","method":"In vitro editing assay, immunoprecipitation dimerization assay, adenoviral in vivo delivery to mouse liver","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis combined with in vitro and in vivo functional validation, mechanistic link between dimerization and activity established","pmids":["8999814"],"is_preprint":false},{"year":1998,"finding":"The 65-kDa complementing activity (later identified as ACF) binds specifically to the mooring sequence of apoB mRNA (not antisense or mooring-sequence mutants) in the absence of apobec-1, and also interacts with apobec-1, supporting a model where it is the RNA-binding subunit of the holoenzyme.","method":"RNA affinity chromatography, UV cross-linking, far-Western analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical purification with multiple orthogonal methods (affinity chromatography, UV cross-linking, far-Western), rigorous mooring-sequence mutant controls","pmids":["9671452"],"is_preprint":false},{"year":2000,"finding":"APOBEC1 complementation factor (ACF), a 64.3-kDa protein with three RNA recognition motifs, is identified and purified; ACF and apobec-1 constitute the minimal protein requirements for apoB mRNA editing in vitro. ACF binds apoB mRNA via the mooring sequence (UV cross-linking, immunoprecipitation), and ACF-apobec-1 complex forms in transfected cells. Immunodepletion of ACF from liver extracts abolishes editing.","method":"Protein purification, peptide sequencing, molecular cloning, UV cross-linking, immunoprecipitation, co-immunoprecipitation, immunodepletion, in vitro editing reconstitution","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — purification to homogeneity, in vitro reconstitution with minimal components, multiple orthogonal methods, immunodepletion rescue","pmids":["10669759"],"is_preprint":false},{"year":2000,"finding":"APOBEC1 binds AU-rich sequences with consensus UUUN[A/U]U (Kd ~50 nM for high-affinity sites, ~435 nM for apoB RNA); binding of APOBEC1 to this consensus in c-myc 3'UTR stabilizes c-myc mRNA (half-life increased from 90 to 240 min), an effect abolished by RNA-binding–deficient APOBEC1 mutants.","method":"Filter binding assays, circular permutation analysis, RNA secondary structure prediction, mRNA half-life assay with actinomycin D, transfection of APOBEC1 expression mutants","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro binding assays with Kd measurements plus in vivo mRNA stability assay with mutant controls, multiple orthogonal methods","pmids":["10688645"],"is_preprint":false},{"year":2000,"finding":"GRY-RBP, an RNA-binding protein with ~50% homology to ACF, is a component of the apoB mRNA editosome; it binds both ACF and apobec-1, binds apoB RNA, and inhibits C-to-U editing by sequestering ACF (competitive inhibition rescued by excess ACF). Antisense knockdown of GRY-RBP in hepatoma cells increases apoB RNA editing.","method":"Yeast two-hybrid, two-hybrid screen, peptide sequencing of active fraction, recombinant protein binding assays, immunodepletion, antisense knockdown, co-localization in transfected cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple biochemical methods including pulldown, functional reconstitution, antisense knockdown, and co-localization","pmids":["11134005"],"is_preprint":false},{"year":2001,"finding":"CUGBP2 is a component of the apoB mRNA editing holoenzyme; it co-fractionates with ACF, immunodepletion of CUGBP2 co-precipitates ACF, CUGBP2 binds apoB RNA at an AU-rich sequence upstream of the edited cytidine, and addition of recombinant CUGBP2 dose-dependently inhibits C-to-U editing rescued by apobec-1 or ACF.","method":"Co-fractionation, immunodepletion, co-immunoprecipitation, UV cross-linking, in vitro editing reconstitution, antisense knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple biochemical and cell-based assays, antisense knockdown with editing readout, inhibitor rescue experiment","pmids":["11577082"],"is_preprint":false},{"year":2001,"finding":"ARCD-1, an apobec-1 homologue, has cytidine deaminase and apoB RNA binding activity but cannot mediate C-to-U RNA editing; it interacts with and heterodimerizes with apobec-1 and ACF, acting as a dominant negative inhibitor of apoB mRNA editing.","method":"Recombinant protein activity assays, heterodimerization immunoprecipitation, in vitro and in vivo editing assays, subcellular localization","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and cell-based assays, single lab, multiple methods but ARCD-1 is a paralog, not APOBEC1 itself; mechanistically informs APOBEC1 dimerization","pmids":["11698249"],"is_preprint":false},{"year":2001,"finding":"ABBP-2, a DnaJ/Hsp40 homologue identified by yeast two-hybrid, binds apobec-1 via its J domain and G/F domain; knockdown of ABBP-2 inhibits apoB mRNA editing; editing activity of tissue extracts requires Hsp70/ABBP-2 and is abolished by removal of endogenous ATP (which disrupts ABBP-2–Hsp70 interaction), implicating a chaperone function in editosome assembly.","method":"Yeast two-hybrid, domain deletion mapping, transfection GFP fusion, antisense knockdown in cells, in vitro editing assay with ATP depletion, Hsp70 co-IP","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus in vitro functional assays and cell-based knockdown, single lab","pmids":["11584023"],"is_preprint":false},{"year":2001,"finding":"ACF domains required for RNA binding and apobec-1 interaction were mapped: the N-terminal RRMs (especially RRM1 and RRM2) together with the pre-RRM region are necessary for apoB mRNA binding and complementing activity; the auxiliary domain RG-rich region is required for RNA binding and apobec-1 interaction; the RRMs are also required for apobec-1 interaction.","method":"Deletion and point mutagenesis of ACF, in vitro binding assays (Kd measurements), in vitro editing complementation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis with quantitative binding assays and functional reconstitution, single lab but multiple orthogonal methods","pmids":["11571303"],"is_preprint":false},{"year":2001,"finding":"ACF is a nuclear protein that upon co-transfection with apobec-1 promotes nuclear co-localization of apobec-1 (which is otherwise predominantly cytoplasmic); protein–protein interaction between ACF and apobec-1 is required for nuclear import of apobec-1; ACF NLS mutants that cannot interact with apobec-1 leave apobec-1 in the cytoplasm.","method":"Transfection of ACF/APOBEC1 constructs, immunofluorescence co-localization, deletion/mutation of NLS","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based localization with mutant controls, single lab","pmids":["11571303"],"is_preprint":false},{"year":2002,"finding":"ACF binds single-stranded but not double-stranded apoB mRNA with high affinity; all three RRMs contribute to RNA binding; point mutations in RRM1 or RRM2 decrease Kd for apoB mRNA by two orders of magnitude; the pre-RRM region is required for complementing activity and RNA binding but not for apobec-1 interaction.","method":"Deletion mutagenesis, point mutagenesis, binding assays with Kd measurements, in vitro editing complementation assay","journal":"RNA","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis with quantitative binding measurements and reconstitution, single lab","pmids":["11871661"],"is_preprint":false},{"year":2002,"finding":"APOBEC1 and its homologs APOBEC3C and APOBEC3G exhibit DNA mutator activity in E. coli through cytosine deamination (dC→dU), with each protein showing distinct local target sequence specificity.","method":"E. coli rifampicin-resistance mutation assay, expression of APOBEC1 and homologs in bacteria","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional bacterial assay with defined readout, single lab, replicated for multiple family members","pmids":["12453430"],"is_preprint":false},{"year":2003,"finding":"APOBEC1 deaminates cytosine to uracil in single-stranded DNA in vitro (using partially purified APOBEC1 from E. coli extracts); activity is specific for ssDNA (not dsDNA) and exhibits local sequence context dependence.","method":"In vitro biochemical deamination assay using partially purified recombinant APOBEC1, substrate specificity characterization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro enzyme assay with purified protein, ssDNA vs dsDNA specificity established biochemically","pmids":["12697753"],"is_preprint":false},{"year":2003,"finding":"ACF localizes to the nucleus via a novel 41-residue nuclear localization signal (ANS) in its auxiliary domain; ACF is a nucleocytoplasmic shuttling protein (confirmed by heterokaryon assay); nuclear accumulation is CRM1-dependent for export and transportin-2–dependent for import; transportin 2 binds directly to the ANS motif.","method":"GFP/β-galactosidase chimera nuclear localization assay, actinomycin D treatment, leptomycin B CRM1 inhibition, heterokaryon assay, co-immunoprecipitation with transportin 2, confocal microscopy","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell-based assays with pharmacological and genetic controls, co-IP of binding partner; concerns ACF not APOBEC1 directly but relevant to APOBEC1 nuclear import","pmids":["12896982"],"is_preprint":false},{"year":2004,"finding":"Crystal structure of yeast CDD1, an APOBEC1 ortholog, at 2.0-Å resolution reveals the fold; comparative modeling of APOBEC1 indicates dimerization and trans-acting loops contributing to active site formation; a central active site 'flap' accommodates large substrates (RNA or ssDNA), explaining equal likelihood of APOBEC1 binding ssDNA or RNA.","method":"X-ray crystallography of CDD1, comparative structural modeling of APOBEC1 and AID","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — crystal structure of ortholog plus comparative modeling; APOBEC1 structure itself not directly solved in this study","pmids":["15148397"],"is_preprint":false},{"year":2004,"finding":"Purified APOBEC1 apoenzyme has intrinsic residual editing activity on a minimal apoB mRNA substrate without auxiliary factors; ACF broadens the temperature range and lowers the optimal temperature for editing activity, consistent with ACF promoting a conformational transition in the RNA substrate.","method":"Expression and purification to homogeneity of APOBEC1, in vitro editing kinetics assay with and without ACF, factorial and response surface experimental design","journal":"RNA","confidence":"High","confidence_rationale":"Tier 1 / Moderate — purified protein reconstitution with kinetic characterization and auxiliary factor comparison, single lab but rigorous biochemistry","pmids":["15273326"],"is_preprint":false},{"year":2004,"finding":"Apobec-1 binds to AU-rich sequences in the COX-2 mRNA 3'UTR (first 60 nt) via EMSA and UV cross-linking, stabilizing COX-2 mRNA; apobec-1-knockout mice show reduced COX-2 induction and intestinal stem cell survival after gamma-irradiation, an effect mediated through COX-2/prostaglandin E2.","method":"EMSA, UV cross-linking, mRNA half-life assay with chimeric luciferase-COX-2 3'UTR reporter, apobec-1 knockout mice with irradiation model, real-time PCR, Western blot","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro binding assays plus in vivo knockout phenotype with molecular mechanism, multiple orthogonal methods","pmids":["15480992"],"is_preprint":false},{"year":2005,"finding":"NMR structure of the 31-nt apoB mRNA stem-loop shows the edited cytidine (C6666) is stacked in a loop and inaccessible to APOBEC1 alone; APOBEC1 does not specifically bind apoB mRNA by itself but requires ACF, which recognizes the flexible mooring sequence and melts the stem-loop to expose C6666 to APOBEC1.","method":"NMR structure determination of apoB mRNA stem-loop, RNA binding assays with APOBEC1 and ACF","journal":"RNA","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure plus functional RNA binding analysis, provides mechanistic explanation for ACF requirement","pmids":["15659357"],"is_preprint":false},{"year":2006,"finding":"APOBEC1 and AID are nucleo-cytoplasmic trafficking proteins, whereas APOBEC3G is strongly retained in the cytoplasm through mechanisms involving both N- and C-terminal regions.","method":"Subcellular fractionation, nucleo-cytoplasmic shuttling assays in cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based localization assays, single lab, direct comparison of family members","pmids":["16999936"],"is_preprint":false},{"year":2006,"finding":"ACF phosphorylation (on serine residues, predominantly by protein phosphatase I-sensitive kinase) regulates apoB mRNA editing: phosphorylated ACF is restricted to nuclei and co-sediments with editing-competent 27S complexes; alkaline phosphatase treatment reduces APOBEC-1 co-immunoprecipitation with ACF and inhibits editing; ethanol stimulates both ACF phosphorylation and editing.","method":"Co-immunoprecipitation, alkaline phosphatase treatment of nuclear extracts, glycerol gradient sedimentation, two-dimensional phosphoamino acid analysis, protein phosphatase inhibitor treatment in primary hepatocytes","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple biochemical methods linking ACF phosphorylation to editosome assembly and APOBEC1 interaction, in vitro and cell-based evidence","pmids":["16820530"],"is_preprint":false},{"year":2006,"finding":"ACF phosphorylation at S154 and S368 by PKC regulates apoB mRNA editing; PKC activation stimulates editing and ACF phosphorylation; S154A/S368A mutations inhibit ethanol-stimulated editing; S154D/S368D phosphomimetics stimulate editing to levels comparable to ethanol treatment.","method":"PKC/PKA pharmacological activation in primary hepatocytes, in vitro phosphorylation of purified ACF by PKC, site-directed mutagenesis (alanine/aspartate substitutions), in vitro editing assay","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro phosphorylation with purified protein combined with mutagenesis and cell-based functional assay, single lab","pmids":["17229474"],"is_preprint":false},{"year":2007,"finding":"Deletion of apobec-1 in Apc(min/+) mice dramatically reduces intestinal adenoma formation, associated with increased apoptosis, reduced proliferation, reduced COX-2 mRNA (~2-fold vs. adenomas), and reduced expression of other AU-rich mRNA targets (EGFR, PPARδ, EP4, c-myc) containing the apobec-1 consensus binding site. Adenoviral apobec-1 in HCA-7 cells dose-dependently increases COX-2 protein and stabilizes COX-2 mRNA.","method":"Genetic epistasis (compound Apc(min/+) apobec-1(-/-) mice), intestinal adenoma counting, apoptosis and proliferation assays, mRNA quantification, adenoviral apobec-1 delivery in cancer cells","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with multiple molecular readouts plus cell-based confirmation, multiple orthogonal methods","pmids":["17875695"],"is_preprint":false},{"year":2009,"finding":"APOBEC1 binds to AU-rich regions of the Cyp7a1 mRNA 3'UTR containing the UUUN(A/U)U consensus, as shown by UV cross-linking and in vivo RNA co-immunoprecipitation; Apobec-1-knockout mice show decreased Cyp7a1 mRNA and protein (without changes in transcription), increased gallstone susceptibility, and adenoviral Apobec-1 rescue restores Cyp7a1 expression.","method":"UV cross-linking to recombinant APOBEC1, in vivo RNA co-immunoprecipitation, Cyp7a1 transcription run-on, adenoviral rescue in knockout mice, lithogenic diet model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro binding plus in vivo RNA co-IP plus knockout/rescue experiment, multiple orthogonal methods","pmids":["19386592"],"is_preprint":false},{"year":2011,"finding":"APOBEC1 edits multiple mRNA targets (32 validated) located in AU-rich segments of transcript 3'UTRs, identified by transcriptome-wide comparative RNA-Seq of APOBEC1-expressing vs. non-expressing conditions; editing sites share characteristic sequence features.","method":"Transcriptome-wide comparative RNA-Seq (APOBEC1+ vs. control), Sanger sequence validation of editing sites","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased genome-wide approach with validation, dramatically expanded known substrate repertoire","pmids":["21258325"],"is_preprint":false},{"year":2011,"finding":"APOBEC1 (A1) restricts LINE-1 and LTR retrotransposons (IAP, MusD) in cell-culture retrotransposition assays; anti-L1 activity is deamination-independent, whereas inhibition of LTR-retrotransposons requires deaminase activity; restriction is not affected by subcellular localization.","method":"Cell culture-based retrotransposition assays, deaminase-inactive mutant controls, subcellular localization experiments","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based functional assay with catalytic mutant controls distinguishing two mechanisms, single lab","pmids":["21398638"],"is_preprint":false},{"year":2014,"finding":"RBM47 is a novel RNA-binding protein that interacts with APOBEC1 and A1CF; RBM47 can substitute for A1CF in APOBEC1-mediated C-to-U RNA editing in vitro and is necessary and sufficient for APOBEC1-mediated editing; Rbm47-deficient mice exhibit impaired RNA editing.","method":"Co-immunoprecipitation of RBM47 with APOBEC1 and A1CF, in vitro editing assay with RBM47, Rbm47 knockout mice","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — protein interaction assays plus in vitro reconstitution plus in vivo knockout, multiple orthogonal methods","pmids":["24916387"],"is_preprint":false},{"year":2014,"finding":"Genome-wide deep sequencing of intestinal and hepatic RNA from wild-type and Apobec-1-deficient mice reveals 56 novel editing sites in 54 intestinal mRNAs and 22 sites in 17 liver mRNAs (all in 3'UTRs); editing leads to corresponding changes in intestinal mRNA and protein levels for 11 genes; Apobec-1 adenoviral or transgenic rescue restores editing; cell-free extracts from wild-type but not Apobec-1(-/-) mice support editing.","method":"Deep sequencing (RNA-Seq), Sanger-sequence validation, tissue-specific Apobec-1 adenoviral and transgenic overexpression rescue, cell-free editing assays, polysome profiling","journal":"Genome biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide approach with knockout/rescue validation and cell-free mechanistic confirmation, multiple orthogonal methods","pmids":["24946870"],"is_preprint":false},{"year":2017,"finding":"A1CF (APOBEC1 complementation factor) is dispensable for C-to-U RNA editing in vivo under normal physiological conditions: A1cf conditional null mice are viable and fertile, with no changes in editing efficiency at multiple targets including ApoB in small intestine and liver.","method":"Conditional A1cf knockout mice, quantitative C-to-U RNA editing at multiple targets in small intestine and liver","journal":"RNA","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with comprehensive editing analysis, contradicts earlier in vitro models, replicated by independent group (PMID:30309881)","pmids":["28069890","30309881"],"is_preprint":false},{"year":2017,"finding":"APOBEC1-mediated RNA editing occurs in microglia and is required for maintaining their resting state; mice lacking APOBEC1 editing function in microglia display progressive age-related neurodegeneration, activated microglial clustering, aberrant myelination, increased inflammation, and lysosomal anomalies with behavioral and motor deficiencies.","method":"APOBEC1 RNA editing analysis in microglia, conditional APOBEC1 knockout mice, histopathological and behavioral phenotyping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo knockout with multiple phenotypic readouts but mechanism linking specific editing targets to phenotype not fully defined from abstract","pmids":["29167375"],"is_preprint":false},{"year":2018,"finding":"A1CF and RBM47 each function independently but interact in a tissue-specific manner to regulate APOBEC1-dependent C-to-U RNA editing; double knockout of A1cf and Rbm47 in liver virtually eliminates apoB RNA editing and reduces most other targets; intestinal double knockout further reduces editing beyond single Rbm47 knockout; forced A1CF expression alone does not restore editing in double knockouts.","method":"Tissue-specific single and double conditional knockouts of A1cf and Rbm47, adenoviral APOBEC1 rescue, RNA-Seq, quantitative editing analysis","journal":"RNA","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with tissue-specific double knockouts and rescue experiments, comprehensive editing analysis","pmids":["30309881"],"is_preprint":false},{"year":2019,"finding":"APOBEC1-RBM47 and APOBEC1-A1CF complexes reconstituted in HEK293T cells show differential RNA editing activity: A1CF and RBM47 differ in their selectivity for specific RNA targets; human vs. mouse versions of cofactors differ in activity; minimal domain of RBM47 required for activity was defined.","method":"Reconstitution of APOBEC1 with either cofactor in HEK293T cells, cell-based fluorescent editing reporter assay, domain deletion analysis of RBM47","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reconstitution in defined cell system with quantitative editing assay and domain mapping, single lab","pmids":["30844405"],"is_preprint":false},{"year":2020,"finding":"Crystal structure of APOBEC1 reveals a typical APOBEC deaminase core plus a unique well-folded hydrophobic C-terminal domain (A1HD) that forms a stable dimer via hydrophobic interactions creating a four-stranded β-sheet positively charged surface; structure-guided mutagenesis shows A1HD directs RNA substrate and cofactor interactions.","method":"X-ray crystallography of APOBEC1, structure-guided mutagenesis, biochemical characterization of RNA/DNA substrate selectivity","journal":"NAR cancer","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus functional mutagenesis, direct structural determination of APOBEC1 itself","pmids":["33094286"],"is_preprint":false},{"year":2021,"finding":"APOBEC1 cytosine deaminase activity on ssDNA is suppressed by replication protein A (RPA) competition for ssDNA; APOBEC1 cannot efficiently compete with RPA in vitro, correlating with low levels of genomic DNA damage (γH2AX foci) in lung cancer cells, suggesting RPA acts as a defense against APOBEC1 off-target deamination.","method":"In vitro ssDNA deamination assay with RPA competition, γH2AX foci assay in lung cancer cell line","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro biochemical assay plus cell-based DNA damage measurement, single lab, mechanistic link between RPA competition and genomic protection established","pmids":["33330905"],"is_preprint":false},{"year":1999,"finding":"APOBEC1 dimerization requires the C-terminal region; N-terminal deletions up to residue A117 do not impair dimerization, while C-terminal deletions reduce it; basic amino acid clusters R15R16R17 and R33K34 are essential for apoB mRNA editing; residues L182, I185, L189 and a β-turn (P190/P191) in the leucine-rich C-terminal region are required for normal editing function.","method":"Systematic targeted mutagenesis, in vitro apoB mRNA editing assay, immunoprecipitation dimerization assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis with in vitro reconstitution and dimerization assays, comprehensive structure-function analysis","pmids":["10191286"],"is_preprint":false},{"year":2000,"finding":"In yeast expressing APOBEC-1, apoB mRNA editing occurs preferentially in the nucleus; cis-acting sequence requirements and intracellular distribution of APOBEC-1 in yeast are similar to those in mammalian cells, suggesting auxiliary protein functions required for editosome assembly are conserved in yeast.","method":"Yeast expression system for APOBEC-1, apoB mRNA editing assay, intracellular localization","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — heterologous cell system reconstitution with editing activity and localization, single lab","pmids":["10606639"],"is_preprint":false},{"year":2014,"finding":"APOBEC1 expression in chicken DT40 cells increases inactivation of a stably inserted reporter gene and increases imatinib-resistant clones in a human CML model through induction of mutations in BCR-ABL1, demonstrating APOBEC1 acts as a DNA mutator in vertebrate cells.","method":"Reporter gene inactivation assay in DT40 cells, imatinib-resistance mutation induction assay in human CML cells, BCR-ABL1 sequencing","journal":"Genome biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based functional assay with molecular sequencing readout, single lab","pmids":["25085003"],"is_preprint":false},{"year":2014,"finding":"hnRNPQ isoform 6 (hnRNPQ6) is required for efficient interaction of APOBEC1 with IL-8 mRNA in HuH7.5 cells; APOBEC1 binding to AU-rich elements in IL-8 3'UTR extends mRNA half-life and increases IL-8 production in a cell-type-specific and hnRNPQ6-dependent manner.","method":"FLAG-tagged APOBEC1 immunoprecipitation followed by microarray (RNA-IP), siRNA screen, yeast two-hybrid, reporter assay with IL-8 3'UTR-luciferase, mRNA half-life measurement, overexpression of hnRNPQ isoforms","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-IP, siRNA screen, reporter assay and mRNA stability in combination, single lab","pmids":["25100733"],"is_preprint":false}],"current_model":"APOBEC1 is the catalytic cytidine deaminase subunit of the apoB mRNA editing complex, acting within a multiprotein holoenzyme (minimally requiring RBM47, and optionally A1CF, as RNA-binding cofactors) to perform site-specific C-to-U deamination of apoB mRNA at C6666 in the intestine/liver; it functions as a homodimer whose dimerization, zinc-coordinating residues (His61, Cys93, Cys96), catalytic Glu63, and C-terminal hydrophobic domain are all required for activity; beyond apoB mRNA, APOBEC1 binds AU-rich 3'UTR sequences (consensus UUUN[A/U]U) in dozens of mRNA targets to stabilize them (e.g., COX-2, c-myc, Cyp7a1, IL-8); it can also deaminate cytosines in single-stranded DNA (suppressed by RPA competition) and restrict retroelements via both deaminase-dependent and -independent mechanisms; its nuclear activity is regulated by ACF/RBM47 cofactor phosphorylation and nucleo-cytoplasmic shuttling, while microglia-specific APOBEC1-mediated RNA editing is required for maintaining CNS homeostasis."},"narrative":{"mechanistic_narrative":"APOBEC1 is the catalytic zinc-dependent cytidine deaminase that performs site-specific C-to-U editing of apoB mRNA at the canonical site, and its targeted disruption in mice abolishes all apoB mRNA editing and eliminates serum apoB48, establishing it as the essential and non-redundant catalytic component of the editing apparatus [PMID:7782343, PMID:8621694, PMID:8824235]. Its activity depends on zinc-coordinating residues (His61, Cys93, Cys96) and catalytic Glu63, while a leucine-rich C-terminal region and basic N-terminal clusters are additionally required for RNA editing; the enzyme functions as a homodimer, and dimerization-competent inactive mutants act as dominant negatives [PMID:7782343, PMID:10191286, PMID:8999814]. The crystal structure of APOBEC1 shows a deaminase core plus a unique hydrophobic C-terminal domain (A1HD) that mediates stable dimerization and directs RNA substrate and cofactor interactions [PMID:33094286]. APOBEC1 alone cannot specifically bind the apoB stem-loop, in which the target cytidine C6666 is sequestered; an RNA-binding cofactor recognizes the mooring sequence and melts the stem-loop to present the substrate [PMID:15659357]. Two cofactors fulfill this role: A1CF (ACF) was identified biochemically as the minimal complementing factor in vitro [PMID:10669759], but genetic studies showed RBM47 is necessary and sufficient for editing and that A1CF is dispensable in vivo, with the two acting tissue-specifically and redundantly such that combined loss eliminates editing [PMID:24916387, PMID:28069890, PMID:30309881]. Beyond mRNA editing, APOBEC1 binds AU-rich 3'UTR sequences with consensus UUUN[A/U]U to stabilize target mRNAs including c-myc, COX-2, and Cyp7a1, linking it to intestinal stem cell survival, adenoma formation, and bile acid/gallstone physiology [PMID:10688645, PMID:15480992, PMID:17875695, PMID:19386592]. Transcriptome-wide sequencing established dozens of physiological 3'UTR editing targets in intestine and liver [PMID:21258325, PMID:24946870]. APOBEC1 also deaminates cytosines in single-stranded DNA, acting as a vertebrate DNA mutator whose off-target activity is restrained by RPA competition, and it restricts LINE-1 and LTR retrotransposons through both deaminase-dependent and -independent mechanisms [PMID:12697753, PMID:25085003, PMID:33330905, PMID:21398638]. Microglial APOBEC1-mediated RNA editing is required to maintain CNS homeostasis, with its loss causing progressive neurodegeneration [PMID:29167375].","teleology":[{"year":1995,"claim":"Defined which residues and domains of APOBEC1 underlie catalysis versus RNA recognition, separating the deaminase chemistry from editing-specific requirements.","evidence":"Site-directed mutagenesis of GST-APOBEC1 with in vitro deaminase, editing, and UV cross-linking RNA-binding assays in McA7777 cells","pmids":["7782343","7782342"],"confidence":"High","gaps":["Did not establish whether APOBEC1 acts alone or requires cofactors for editing","Structural basis of domain functions not resolved"]},{"year":1996,"claim":"Established APOBEC1 as the essential, non-redundant catalytic component of apoB mRNA editing in vivo.","evidence":"Targeted apobec-1 knockout mice with apoB mRNA editing analysis and serum apoB48 Western blot","pmids":["8621694","8824235"],"confidence":"High","gaps":["Did not identify the auxiliary factors required for editing","Overexpression caused promiscuous hyperediting, implying tight regulation not yet explained"]},{"year":1996,"claim":"Demonstrated that APOBEC1 alone is insufficient and requires a directly-interacting auxiliary complementing protein for editing.","evidence":"APOBEC1 affinity chromatography, depletion/reconstitution of in vitro editing, glycerol gradient sedimentation","pmids":["8910449"],"confidence":"High","gaps":["Identity of the 65 kDa complementing protein not yet determined","Stoichiometry of the holoenzyme unknown"]},{"year":1999,"claim":"Mapped the structural determinants of APOBEC1 homodimerization to the C-terminal region and identified basic clusters required for editing.","evidence":"Systematic targeted mutagenesis with in vitro editing and immunoprecipitation dimerization assays","pmids":["10191286"],"confidence":"High","gaps":["Atomic structure of the dimer interface not resolved at this stage"]},{"year":2000,"claim":"Identified and purified ACF as the RNA-binding subunit, defining the minimal two-protein editing holoenzyme.","evidence":"Protein purification, peptide sequencing, cloning, UV cross-linking, co-IP, immunodepletion and in vitro reconstitution","pmids":["10669759","9671452"],"confidence":"High","gaps":["Did not test whether ACF is the sole physiological cofactor in vivo","Mechanism of mooring-sequence recognition not structurally defined"]},{"year":2000,"claim":"Revealed a deaminase-independent role: APOBEC1 binds AU-rich 3'UTR consensus sequences to stabilize target mRNAs such as c-myc.","evidence":"Filter binding with Kd measurements, circular permutation, mRNA half-life assay with mutant controls","pmids":["10688645"],"confidence":"High","gaps":["Physiological significance of mRNA stabilization not yet shown in vivo at this point"]},{"year":2001,"claim":"Characterized additional editosome-associated RNA-binding proteins and their regulatory roles in editing.","evidence":"Yeast two-hybrid, immunodepletion, antisense knockdown, in vitro editing reconstitution for GRY-RBP, CUGBP2, ABBP-1, ABBP-2, and the dominant-negative paralog ARCD-1","pmids":["11134005","11577082","8999813","11584023","11698249"],"confidence":"Medium","gaps":["In vivo requirement of these accessory factors not established by knockout","Most identified by single-lab two-hybrid plus in vitro assays"]},{"year":2001,"claim":"Showed that ACF mediates nuclear import of cytoplasmic APOBEC1, coupling cofactor binding to subcellular localization.","evidence":"Co-transfection immunofluorescence with ACF NLS mutants and domain mapping","pmids":["11571303"],"confidence":"Medium","gaps":["Single lab cell-based localization","Did not define import machinery used"]},{"year":2005,"claim":"Provided the structural rationale for the cofactor requirement by showing the target cytidine is sequestered in the apoB stem-loop and exposed only via ACF-mediated melting.","evidence":"NMR structure of the 31-nt apoB stem-loop and RNA binding assays with APOBEC1 and ACF","pmids":["15659357"],"confidence":"High","gaps":["No co-structure of the assembled holoenzyme on RNA","Apoenzyme retains residual activity, complicating a strict obligate-cofactor model"]},{"year":2006,"claim":"Linked cofactor phosphorylation to editosome assembly, establishing a signaling-responsive regulatory layer.","evidence":"Co-IP, alkaline phosphatase treatment, glycerol gradient sedimentation, PKC phosphorylation and S154/S368 phosphomimetic mutagenesis in hepatocytes","pmids":["16820530","17229474"],"confidence":"High","gaps":["Whether APOBEC1 itself is phosphorylated not addressed","Physiological signals beyond ethanol/PKC not delineated"]},{"year":2004,"claim":"Extended the AU-rich-binding/mRNA-stabilization function to physiology, connecting APOBEC1 to COX-2 stabilization and intestinal stem cell survival.","evidence":"EMSA, UV cross-linking, luciferase-3'UTR reporter half-life, and apobec-1 knockout irradiation mouse model","pmids":["15480992"],"confidence":"High","gaps":["Did not distinguish stabilization from editing for the same targets in vivo"]},{"year":2007,"claim":"Established a tumor-promoting role through stabilization of AU-rich oncogenic mRNAs in the intestine.","evidence":"Compound Apc(min/+) apobec-1(-/-) genetic epistasis, adenoma counting, mRNA quantification, adenoviral rescue in cancer cells","pmids":["17875695"],"confidence":"High","gaps":["Relative contribution of editing vs. stabilization to tumorigenesis not separated"]},{"year":2009,"claim":"Demonstrated post-transcriptional control of bile acid metabolism via APOBEC1 binding and stabilization of Cyp7a1 mRNA.","evidence":"UV cross-linking, in vivo RNA co-IP, transcription run-on, adenoviral rescue and lithogenic diet in knockout mice","pmids":["19386592"],"confidence":"High","gaps":["Cofactor dependence of Cyp7a1 binding not defined"]},{"year":2011,"claim":"Defined a genome-wide repertoire of APOBEC1 C-to-U editing targets concentrated in AU-rich 3'UTRs.","evidence":"Transcriptome-wide comparative RNA-Seq with Sanger validation; cell-based and in vivo follow-up","pmids":["21258325","24946870"],"confidence":"High","gaps":["Functional consequences for most edited transcripts not characterized","Cofactor used per target not assigned"]},{"year":2014,"claim":"Identified RBM47 as a cofactor that is necessary and sufficient for editing in vivo, reframing the ACF-centric model.","evidence":"Co-IP with APOBEC1 and A1CF, in vitro reconstitution, and Rbm47 knockout mice","pmids":["24916387"],"confidence":"High","gaps":["Tissue-specific division of labor between cofactors not yet resolved"]},{"year":2014,"claim":"Characterized APOBEC1 as a vertebrate ssDNA DNA mutator capable of inducing drug-resistance mutations.","evidence":"Reporter inactivation in DT40 cells and imatinib-resistance/BCR-ABL1 mutation assay in CML cells; in vitro ssDNA deamination","pmids":["25085003","12697753","12453430"],"confidence":"Medium","gaps":["Genomic mutagenesis significance in normal tissues unclear","Cell-based assays from single labs"]},{"year":2017,"claim":"Showed A1CF is dispensable for physiological editing in vivo and revealed an APOBEC1 RNA-editing requirement in microglia for CNS homeostasis.","evidence":"A1cf conditional knockout editing analysis; microglia-specific APOBEC1 editing loss with neuropathological and behavioral phenotyping","pmids":["28069890","30309881","29167375"],"confidence":"Medium","gaps":["Specific microglial editing targets driving neurodegeneration not identified","Mechanism linking editing to resting-state maintenance unresolved"]},{"year":2018,"claim":"Resolved cofactor redundancy by showing A1CF and RBM47 act tissue-specifically with combined loss eliminating editing.","evidence":"Tissue-specific single and double conditional A1cf/Rbm47 knockouts with adenoviral rescue and RNA-Seq editing analysis","pmids":["30309881"],"confidence":"High","gaps":["Determinants of which cofactor selects which target only partly defined"]},{"year":2020,"claim":"Provided the APOBEC1 crystal structure, defining the A1HD dimerization domain that directs RNA and cofactor interactions.","evidence":"X-ray crystallography of APOBEC1 with structure-guided mutagenesis and substrate selectivity assays","pmids":["33094286"],"confidence":"High","gaps":["No structure of APOBEC1 bound to cofactor or RNA substrate"]},{"year":2021,"claim":"Showed RPA competition for ssDNA limits APOBEC1 off-target genomic deamination, defining a cellular defense against its mutator activity.","evidence":"In vitro ssDNA deamination with RPA competition and γH2AX foci in lung cancer cells","pmids":["33330905"],"confidence":"Medium","gaps":["In vivo relevance of RPA protection not established","Single-lab study"]},{"year":null,"claim":"It remains unresolved how cofactor identity (A1CF vs RBM47) and tissue context determine target selection, and which specific edited transcripts mediate the microglial/CNS homeostasis function.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No holoenzyme-on-RNA structure","Target-specificity rules of each cofactor undefined","Causal microglial editing targets unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,2,21,29,32]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[18,17,41,38]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[1,9,23,28]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,18]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[9,22,28]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[15,24]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[15,40,24]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[2,8,29,32]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[28,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[27,41]}],"complexes":["apoB mRNA editing holoenzyme (editosome)"],"partners":["A1CF","RBM47","GRY-RBP","CUGBP2","HNRNPQ"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P41238","full_name":"C->U-editing enzyme APOBEC-1","aliases":["Apolipoprotein B mRNA-editing enzyme catalytic subunit 1","APO1","APOBEC-1","Apolipoprotein B mRNA-editing enzyme 1","HEPR","mRNA(cytosine(6666)) deaminase 1"],"length_aa":236,"mass_kda":28.2,"function":"Cytidine deaminase catalyzing the cytidine to uridine postranscriptional editing of a variety of mRNAs (PubMed:30844405). Form complexes with cofactors that confer differential editing activity and selectivity. Responsible for the postranscriptional editing of a CAA codon for Gln to a UAA codon for stop in the apolipoprotein B mRNA (PubMed:24916387). Also involved in CGA (Arg) to UGA (Stop) editing in the NF1 mRNA (PubMed:11727199). May also play a role in the epigenetic regulation of gene expression by participating in DNA demethylation (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P41238/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOBEC1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOBEC1","total_profiled":1310},"omim":[{"mim_id":"618199","title":"APOBEC1 COMPLEMENTATION FACTOR; A1CF","url":"https://www.omim.org/entry/618199"},{"mim_id":"616686","title":"SYNAPTOTAGMIN-BINDING CYTOPLASMIC RNA-INTERACTING PROTEIN; SYNCRIP","url":"https://www.omim.org/entry/616686"},{"mim_id":"613113","title":"NEUROFIBROMIN 1; NF1","url":"https://www.omim.org/entry/613113"},{"mim_id":"611341","title":"DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 11; DNAJB11","url":"https://www.omim.org/entry/611341"},{"mim_id":"609908","title":"APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 4; APOBEC4","url":"https://www.omim.org/entry/609908"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":27.3}],"url":"https://www.proteinatlas.org/search/APOBEC1"},"hgnc":{"alias_symbol":["BEDP","CDAR1","APOBEC-1","HEPR"],"prev_symbol":[]},"alphafold":{"accession":"P41238","domains":[{"cath_id":"3.40.140.10","chopping":"9-171","consensus_level":"medium","plddt":90.452,"start":9,"end":171},{"cath_id":"-","chopping":"172-236","consensus_level":"medium","plddt":86.8631,"start":172,"end":236}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P41238","model_url":"https://alphafold.ebi.ac.uk/files/AF-P41238-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P41238-F1-predicted_aligned_error_v6.png","plddt_mean":87.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOBEC1","jax_strain_url":"https://www.jax.org/strain/search?query=APOBEC1"},"sequence":{"accession":"P41238","fasta_url":"https://rest.uniprot.org/uniprotkb/P41238.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P41238/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P41238"}},"corpus_meta":[{"pmid":"12453430","id":"PMC_12453430","title":"RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators.","date":"2002","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12453430","citation_count":478,"is_preprint":false},{"pmid":"10669759","id":"PMC_10669759","title":"Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10669759","citation_count":215,"is_preprint":false},{"pmid":"21258325","id":"PMC_21258325","title":"Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs.","date":"2011","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21258325","citation_count":194,"is_preprint":false},{"pmid":"18068040","id":"PMC_18068040","title":"Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice.","date":"2007","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/18068040","citation_count":138,"is_preprint":false},{"pmid":"8626621","id":"PMC_8626621","title":"Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8626621","citation_count":129,"is_preprint":false},{"pmid":"12697753","id":"PMC_12697753","title":"In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1).","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12697753","citation_count":114,"is_preprint":false},{"pmid":"7782343","id":"PMC_7782343","title":"Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7782343","citation_count":112,"is_preprint":false},{"pmid":"7782342","id":"PMC_7782342","title":"apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7782342","citation_count":108,"is_preprint":false},{"pmid":"20836050","id":"PMC_20836050","title":"APOBEC-1-mediated RNA editing.","date":"2010","source":"Wiley interdisciplinary reviews. Systems biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20836050","citation_count":102,"is_preprint":false},{"pmid":"24916387","id":"PMC_24916387","title":"C to U RNA editing mediated by APOBEC1 requires RNA-binding protein RBM47.","date":"2014","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/24916387","citation_count":94,"is_preprint":false},{"pmid":"7768898","id":"PMC_7768898","title":"Alternative mRNA splicing and differential promoter utilization determine tissue-specific expression of the apolipoprotein B mRNA-editing protein (Apobec1) gene in mice. Structure and evolution of Apobec1 and related nucleoside/nucleotide deaminases.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7768898","citation_count":93,"is_preprint":false},{"pmid":"25085003","id":"PMC_25085003","title":"The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas.","date":"2014","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/25085003","citation_count":85,"is_preprint":false},{"pmid":"11134005","id":"PMC_11134005","title":"Identification of GRY-RBP as an apolipoprotein B RNA-binding protein that interacts with both apobec-1 and apobec-1 complementation factor to modulate C to U editing.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11134005","citation_count":85,"is_preprint":false},{"pmid":"11577082","id":"PMC_11577082","title":"Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11577082","citation_count":84,"is_preprint":false},{"pmid":"8621694","id":"PMC_8621694","title":"Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8621694","citation_count":83,"is_preprint":false},{"pmid":"8824235","id":"PMC_8824235","title":"Complete phenotypic characterization of apobec-1 knockout mice with a wild-type genetic background and a human apolipoprotein B transgenic background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of Apobec-1.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8824235","citation_count":83,"is_preprint":false},{"pmid":"8999813","id":"PMC_8999813","title":"Cloning of an Apobec-1-binding protein that also interacts with apolipoprotein B mRNA and evidence for its involvement in RNA editing.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8999813","citation_count":83,"is_preprint":false},{"pmid":"24946870","id":"PMC_24946870","title":"Genome-wide identification and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small intestine and liver.","date":"2014","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/24946870","citation_count":82,"is_preprint":false},{"pmid":"10688645","id":"PMC_10688645","title":"An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3' untranslated region of c-myc increases mRNA stability.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10688645","citation_count":74,"is_preprint":false},{"pmid":"15148397","id":"PMC_15148397","title":"The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15148397","citation_count":74,"is_preprint":false},{"pmid":"18983852","id":"PMC_18983852","title":"Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo.","date":"2008","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18983852","citation_count":63,"is_preprint":false},{"pmid":"9084497","id":"PMC_9084497","title":"Apobec-1 and apolipoprotein B mRNA editing.","date":"1997","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9084497","citation_count":58,"is_preprint":false},{"pmid":"11871661","id":"PMC_11871661","title":"Identification of domains in apobec-1 complementation factor required for RNA binding and apolipoprotein-B mRNA editing.","date":"2002","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11871661","citation_count":56,"is_preprint":false},{"pmid":"8626710","id":"PMC_8626710","title":"Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8626710","citation_count":55,"is_preprint":false},{"pmid":"10469298","id":"PMC_10469298","title":"Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1.","date":"1999","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10469298","citation_count":53,"is_preprint":false},{"pmid":"21398638","id":"PMC_21398638","title":"Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21398638","citation_count":52,"is_preprint":false},{"pmid":"11727199","id":"PMC_11727199","title":"C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11727199","citation_count":52,"is_preprint":false},{"pmid":"8910449","id":"PMC_8910449","title":"Apobec-1 interacts with a 65-kDa complementing protein to edit apolipoprotein-B mRNA in vitro.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8910449","citation_count":51,"is_preprint":false},{"pmid":"8727508","id":"PMC_8727508","title":"Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits.","date":"1996","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/8727508","citation_count":50,"is_preprint":false},{"pmid":"33445170","id":"PMC_33445170","title":"Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33445170","citation_count":49,"is_preprint":false},{"pmid":"11698249","id":"PMC_11698249","title":"ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing.","date":"2001","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11698249","citation_count":48,"is_preprint":false},{"pmid":"22923694","id":"PMC_22923694","title":"Transgenerational epigenetic effects of the Apobec1 cytidine deaminase deficiency on testicular germ cell tumor susceptibility and embryonic viability.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22923694","citation_count":48,"is_preprint":false},{"pmid":"9671452","id":"PMC_9671452","title":"A sequence-specific RNA-binding protein complements apobec-1 To edit apolipoprotein B mRNA.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9671452","citation_count":47,"is_preprint":false},{"pmid":"16055734","id":"PMC_16055734","title":"Targeted deletion of the murine apobec-1 complementation factor (acf) gene results in embryonic lethality.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16055734","citation_count":45,"is_preprint":false},{"pmid":"10833526","id":"PMC_10833526","title":"Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10833526","citation_count":45,"is_preprint":false},{"pmid":"11571303","id":"PMC_11571303","title":"Mutagenesis of apobec-1 complementation factor reveals distinct domains that modulate RNA binding, protein-protein interaction with apobec-1, and complementation of C to U RNA-editing activity.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11571303","citation_count":44,"is_preprint":false},{"pmid":"30309881","id":"PMC_30309881","title":"Apobec1 complementation factor (A1CF) and RBM47 interact in tissue-specific regulation of C to U RNA editing in mouse intestine and liver.","date":"2018","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30309881","citation_count":42,"is_preprint":false},{"pmid":"25344410","id":"PMC_25344410","title":"High-resolution genetic mapping in the diversity outbred mouse population identifies Apobec1 as a candidate gene for atherosclerosis.","date":"2014","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/25344410","citation_count":42,"is_preprint":false},{"pmid":"12896982","id":"PMC_12896982","title":"A novel nuclear localization signal in the auxiliary domain of apobec-1 complementation factor regulates nucleocytoplasmic import and shuttling.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12896982","citation_count":42,"is_preprint":false},{"pmid":"15659357","id":"PMC_15659357","title":"NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor.","date":"2005","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15659357","citation_count":42,"is_preprint":false},{"pmid":"29167375","id":"PMC_29167375","title":"Loss of APOBEC1 RNA-editing function in microglia exacerbates age-related CNS pathophysiology.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29167375","citation_count":40,"is_preprint":false},{"pmid":"21172829","id":"PMC_21172829","title":"Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function.","date":"2010","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/21172829","citation_count":40,"is_preprint":false},{"pmid":"11584023","id":"PMC_11584023","title":"A DnaJ protein, apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11584023","citation_count":39,"is_preprint":false},{"pmid":"20546753","id":"PMC_20546753","title":"APOBEC1 and APOBEC3 cytidine deaminases as restriction factors for hepadnaviral genomes in non-humans in vivo.","date":"2010","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20546753","citation_count":38,"is_preprint":false},{"pmid":"18971252","id":"PMC_18971252","title":"The antiretroviral potency of APOBEC1 deaminase from small animal species.","date":"2008","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/18971252","citation_count":37,"is_preprint":false},{"pmid":"9346911","id":"PMC_9346911","title":"Partial characterization of the auxiliary factors involved in apolipoprotein B mRNA editing through APOBEC-1 affinity chromatography.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9346911","citation_count":37,"is_preprint":false},{"pmid":"8825867","id":"PMC_8825867","title":"Gene transfer of cytidine deaminase apoBEC-1 lowers lipoprotein(a) in transgenic mice and induces apolipoprotein B editing in rabbits.","date":"1996","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/8825867","citation_count":36,"is_preprint":false},{"pmid":"8999814","id":"PMC_8999814","title":"Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus-mediated transfer of a dominant negative mutant APOBEC-1 leads to increased low density lipoprotein in mice.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8999814","citation_count":36,"is_preprint":false},{"pmid":"21775448","id":"PMC_21775448","title":"APOBEC1-mediated editing and attenuation of herpes simplex virus 1 DNA indicate that neurons have an antiviral role during herpes simplex encephalitis.","date":"2011","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/21775448","citation_count":35,"is_preprint":false},{"pmid":"11352648","id":"PMC_11352648","title":"Two-hybrid cloning identifies an RNA-binding protein, GRY-RBP, as a component of apobec-1 editosome.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11352648","citation_count":35,"is_preprint":false},{"pmid":"16798720","id":"PMC_16798720","title":"PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice.","date":"2006","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16798720","citation_count":35,"is_preprint":false},{"pmid":"10191286","id":"PMC_10191286","title":"Mutational analysis of apolipoprotein B mRNA editing enzyme (APOBEC1). structure-function relationships of RNA editing and dimerization.","date":"1999","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10191286","citation_count":33,"is_preprint":false},{"pmid":"12816761","id":"PMC_12816761","title":"Intestinal lipoprotein assembly in apobec-1-/- mice reveals subtle alterations in triglyceride secretion coupled with a shift to larger lipoproteins.","date":"2003","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12816761","citation_count":33,"is_preprint":false},{"pmid":"11718896","id":"PMC_11718896","title":"Isolation, characterization and developmental regulation of the human apobec-1 complementation factor (ACF) gene.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11718896","citation_count":32,"is_preprint":false},{"pmid":"15480992","id":"PMC_15480992","title":"Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression.","date":"2004","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15480992","citation_count":31,"is_preprint":false},{"pmid":"7595088","id":"PMC_7595088","title":"Developmental regulation of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (APOBEC-1) in human small intestine.","date":"1995","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/7595088","citation_count":31,"is_preprint":false},{"pmid":"20890106","id":"PMC_20890106","title":"apoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20890106","citation_count":29,"is_preprint":false},{"pmid":"28069890","id":"PMC_28069890","title":"APOBEC1 complementation factor (A1CF) is dispensable for C-to-U RNA editing in vivo.","date":"2017","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28069890","citation_count":29,"is_preprint":false},{"pmid":"9797364","id":"PMC_9797364","title":"An alternatively spliced form of apobec-1 messenger RNA is overexpressed in human colon cancer.","date":"1998","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/9797364","citation_count":29,"is_preprint":false},{"pmid":"19843348","id":"PMC_19843348","title":"Human APOBEC1 cytidine deaminase edits HBV DNA.","date":"2009","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/19843348","citation_count":28,"is_preprint":false},{"pmid":"17875695","id":"PMC_17875695","title":"Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17875695","citation_count":28,"is_preprint":false},{"pmid":"9157952","id":"PMC_9157952","title":"Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor-knockout mice by adenovirus-mediated gene delivery of ApoB mRNA editing enzyme (Apobec1).","date":"1997","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9157952","citation_count":28,"is_preprint":false},{"pmid":"15273326","id":"PMC_15273326","title":"Optimization of apolipoprotein B mRNA editing by APOBEC1 apoenzyme and the role of its auxiliary factor, ACF.","date":"2004","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15273326","citation_count":28,"is_preprint":false},{"pmid":"16999936","id":"PMC_16999936","title":"APOBEC-1 and AID are nucleo-cytoplasmic trafficking proteins but APOBEC3G cannot traffic.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16999936","citation_count":27,"is_preprint":false},{"pmid":"14559972","id":"PMC_14559972","title":"RNA-editing cytidine deaminase Apobec-1 is unable to induce somatic hypermutation in mammalian cells.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14559972","citation_count":27,"is_preprint":false},{"pmid":"33330905","id":"PMC_33330905","title":"APOBEC1 cytosine deaminase activity on single-stranded DNA is suppressed by replication protein A.","date":"2021","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/33330905","citation_count":26,"is_preprint":false},{"pmid":"31337756","id":"PMC_31337756","title":"Mitochondrially-targeted APOBEC1 is a potent mtDNA mutator affecting mitochondrial function and organismal fitness in Drosophila.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31337756","citation_count":26,"is_preprint":false},{"pmid":"20406809","id":"PMC_20406809","title":"Apobec-1 complementation factor modulates liver regeneration by post-transcriptional regulation of interleukin-6 mRNA stability.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20406809","citation_count":25,"is_preprint":false},{"pmid":"9186903","id":"PMC_9186903","title":"Characterization of the human apobec-1 gene: expression in gastrointestinal tissues determined by alternative splicing with production of a novel truncated peptide.","date":"1997","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/9186903","citation_count":25,"is_preprint":false},{"pmid":"33094286","id":"PMC_33094286","title":"The structure of APOBEC1 and insights into its RNA and DNA substrate selectivity.","date":"2020","source":"NAR cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33094286","citation_count":24,"is_preprint":false},{"pmid":"30844405","id":"PMC_30844405","title":"Comparison of RNA Editing Activity of APOBEC1-A1CF and APOBEC1-RBM47 Complexes Reconstituted in HEK293T Cells.","date":"2019","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30844405","citation_count":23,"is_preprint":false},{"pmid":"17855359","id":"PMC_17855359","title":"Conditional intestinal lipotoxicity in Apobec-1-/- Mttp-IKO mice: a survival advantage for mammalian intestinal apolipoprotein B mRNA editing.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17855359","citation_count":23,"is_preprint":false},{"pmid":"16820530","id":"PMC_16820530","title":"Metabolic regulation of apoB mRNA editing is associated with phosphorylation of APOBEC-1 complementation factor.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16820530","citation_count":22,"is_preprint":false},{"pmid":"9479499","id":"PMC_9479499","title":"Human apolipoprotein B RNA editing deaminase gene (APOBEC1).","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9479499","citation_count":20,"is_preprint":false},{"pmid":"19386592","id":"PMC_19386592","title":"Decreased expression of cholesterol 7alpha-hydroxylase and altered bile acid metabolism in Apobec-1-/- mice lead to increased gallstone susceptibility.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19386592","citation_count":20,"is_preprint":false},{"pmid":"9672068","id":"PMC_9672068","title":"Distinct promoters induce APOBEC-1 expression in rat liver and intestine.","date":"1998","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9672068","citation_count":19,"is_preprint":false},{"pmid":"10597235","id":"PMC_10597235","title":"Absence of APOBEC-1 mediated mRNA editing in human carcinomas.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10597235","citation_count":19,"is_preprint":false},{"pmid":"9667237","id":"PMC_9667237","title":"Insulin increases expression of apobec-1, the catalytic subunit of the apolipoprotein B mRNA editing complex in rat hepatocytes.","date":"1998","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/9667237","citation_count":19,"is_preprint":false},{"pmid":"14570923","id":"PMC_14570923","title":"Identification of novel alternative splice variants of APOBEC-1 complementation factor with different capacities to support apolipoprotein B mRNA editing.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14570923","citation_count":19,"is_preprint":false},{"pmid":"33057101","id":"PMC_33057101","title":"RNA editing of BFP, a point mutant of GFP, using artificial APOBEC1 deaminase to restore the genetic code.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33057101","citation_count":18,"is_preprint":false},{"pmid":"20348446","id":"PMC_20348446","title":"Hypermutation induced by APOBEC-1 overexpression can be eliminated.","date":"2010","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20348446","citation_count":18,"is_preprint":false},{"pmid":"10502408","id":"PMC_10502408","title":"Disproportionate relationship between APOBEC-1 expression and apolipoprotein B mRNA editing activity.","date":"1999","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/10502408","citation_count":17,"is_preprint":false},{"pmid":"9215539","id":"PMC_9215539","title":"Cloning and characterization of the rat apobec-1 gene: a comparative analysis of gene structure and promoter usage in rat and mouse.","date":"1997","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/9215539","citation_count":17,"is_preprint":false},{"pmid":"25303118","id":"PMC_25303118","title":"Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo.","date":"2014","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/25303118","citation_count":16,"is_preprint":false},{"pmid":"22993231","id":"PMC_22993231","title":"Intestine-specific expression of Apobec-1 rescues apolipoprotein B RNA editing and alters chylomicron production in Apobec1 -/- mice.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22993231","citation_count":16,"is_preprint":false},{"pmid":"15145984","id":"PMC_15145984","title":"Hepatic secretion of small lipoprotein particles in apobec-1-/- mice is regulated by the LDL receptor.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15145984","citation_count":16,"is_preprint":false},{"pmid":"10373583","id":"PMC_10373583","title":"C-->U editing of apolipoprotein B mRNA in marsupials: identification and characterisation of APOBEC-1 from the American opossum Monodelphus domestica.","date":"1999","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10373583","citation_count":16,"is_preprint":false},{"pmid":"8579594","id":"PMC_8579594","title":"In vitro reconstitution of apolipoprotein B RNA editing activity from recombinant APOBEC-1 and McArdle cell extracts.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8579594","citation_count":16,"is_preprint":false},{"pmid":"12374571","id":"PMC_12374571","title":"Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12374571","citation_count":15,"is_preprint":false},{"pmid":"17010310","id":"PMC_17010310","title":"The acidic domain of hnRNPQ (NSAP1) has structural similarity to Barstar and binds to Apobec1.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17010310","citation_count":13,"is_preprint":false},{"pmid":"12020819","id":"PMC_12020819","title":"Apobec-1 transcription in rat colon cancer: decreased apobec-1 protein production through alterations in polysome distribution and mRNA translation associated with upstream AUGs.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12020819","citation_count":13,"is_preprint":false},{"pmid":"9792440","id":"PMC_9792440","title":"Evolutionary origins of the mammalian apolipoproteinB RNA editing enzyme, apobec-1: structural homology inferred from analysis of a cloned chicken small intestinal cytidine deaminase.","date":"1998","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9792440","citation_count":13,"is_preprint":false},{"pmid":"25100733","id":"PMC_25100733","title":"The RNA-editing enzyme APOBEC1 requires heterogeneous nuclear ribonucleoprotein Q isoform 6 for efficient interaction with interleukin-8 mRNA.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25100733","citation_count":12,"is_preprint":false},{"pmid":"10606639","id":"PMC_10606639","title":"APOBEC-1 dependent cytidine to uridine editing of apolipoprotein B RNA in yeast.","date":"2000","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10606639","citation_count":12,"is_preprint":false},{"pmid":"26848653","id":"PMC_26848653","title":"Apobec-1 Complementation Factor (A1CF) Inhibits Epithelial-Mesenchymal Transition and Migration of Normal Rat Kidney Proximal Tubular Epithelial Cells.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26848653","citation_count":12,"is_preprint":false},{"pmid":"24249727","id":"PMC_24249727","title":"The genetic basis for individual differences in mRNA splicing and APOBEC1 editing activity in murine macrophages.","date":"2013","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/24249727","citation_count":12,"is_preprint":false},{"pmid":"28429755","id":"PMC_28429755","title":"Opossum APOBEC1 is a DNA mutator with retrovirus and retroelement restriction activity.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28429755","citation_count":11,"is_preprint":false},{"pmid":"20541536","id":"PMC_20541536","title":"APOBEC-1 complementation factor (ACF) forms RNA-dependent multimers.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20541536","citation_count":11,"is_preprint":false},{"pmid":"17229474","id":"PMC_17229474","title":"Functional characterization of APOBEC-1 complementation factor phosphorylation sites.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17229474","citation_count":11,"is_preprint":false},{"pmid":"20541607","id":"PMC_20541607","title":"Metabolic regulation of APOBEC-1 complementation factor trafficking in mouse models of obesity and its positive correlation with the expression of ApoB protein in hepatocytes.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20541607","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50568,"output_tokens":10635,"usd":0.155614,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21458,"output_tokens":5594,"usd":0.12357,"stage2_stop_reason":"end_turn"},"total_usd":0.279184,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"APOBEC1 (apobec-1) has distinct functional domains: zinc-coordinating residues (His61, Cys93, Cys96) and catalytic Glu63 are required for both cytidine deaminase activity and apoB RNA editing; the leucine-rich region (LRR) is required for RNA editing but not cytidine deaminase activity; His61 is required for RNA binding. Dominant negative mutants (Glu63→Gln, His61→Arg) reduce endogenous editing when overexpressed.\",\n      \"method\": \"Site-directed mutagenesis of GST-fusion APOBEC1, in vitro cytidine deaminase assay, apoB RNA editing assay, UV cross-linking RNA binding assay, transfection into McA 7777 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution + mutagenesis of multiple residues with in vitro assays and in vivo functional validation, multiple orthogonal methods\",\n      \"pmids\": [\"7782343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Recombinant APOBEC1 binds apoB RNA with high specificity via UV cross-linking and EMSA; binding is competed by poly(U) and poly(A,U) but not poly(A); RNA binding specificity for editing is distinct from mooring-sequence dependence.\",\n      \"method\": \"UV cross-linking, electrophoretic mobility shift assay (EMSA), RNA competition assays with recombinant GST/APOBEC-1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with multiple orthogonal binding assays (UV cross-linking + EMSA), rigorous competition controls\",\n      \"pmids\": [\"7782342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Targeted disruption of mouse apobec-1 gene abolishes all apoB mRNA editing and eliminates apoB48 in serum, demonstrating that Apobec-1 is the essential catalytic component with no functional gene duplication.\",\n      \"method\": \"Gene targeting/knockout mice, RNA analysis of apoB mRNA editing, serum apoB48 Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with defined molecular phenotype, replicated in a second independent knockout study (PMID:8824235)\",\n      \"pmids\": [\"8621694\", \"8824235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"APOBEC-1 overexpression in stable hepatoma cell lines causes promiscuous editing of cytidines 5' of the mooring sequence in addition to the canonical site, and this hyperediting is mooring-sequence dependent and proportional to APOBEC-1 levels.\",\n      \"method\": \"Stable cell lines overexpressing APOBEC-1, apoB RNA editing assay, sequencing of editing products\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based loss/gain of function with direct editing readout, single lab\",\n      \"pmids\": [\"8621694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"APOBEC-1 requires auxiliary proteins (complementing activity) for apoB mRNA editing in vitro; recombinant APOBEC-1 immobilized on beads can deplete complementing activity from extracts and reconstitute editing, and the complementing protein (65 kDa) interacts directly with APOBEC-1 independently of apoB mRNA. The C-terminal 59 amino acids of APOBEC-1 are not required for this interaction.\",\n      \"method\": \"APOBEC-1 affinity chromatography, reconstitution in vitro editing assay, size exclusion chromatography, glycerol gradient sedimentation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with affinity chromatography and depletion/rescue experiments, multiple biochemical methods\",\n      \"pmids\": [\"8910449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ABBP-1, a novel RNA-binding protein identified by yeast two-hybrid using apobec-1 as bait, binds apobec-1 via its glycine-rich C-terminal domain, binds apoB mRNA around the editing site, and is required for apoB mRNA editing (immunodepletion abolishes editing; antisense knockdown reduces editing).\",\n      \"method\": \"Yeast two-hybrid, deletion mapping, UV cross-linking to apoB mRNA, immunodepletion from active extracts, antisense knockdown in HepG2 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus in vitro immunodepletion and cell-based knockdown, single lab\",\n      \"pmids\": [\"8999813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"A dominant negative APOBEC-1 mutant (mu1: H61K/C93S/C96S) retains dimerization capacity with wild-type APOBEC-1 and inhibits its editing activity; two other inactive mutants with poor dimerization fail to inhibit, demonstrating that active APOBEC-1 functions as a homodimer and dimerization is required for dominant negative inhibition.\",\n      \"method\": \"In vitro editing assay, immunoprecipitation dimerization assay, adenoviral in vivo delivery to mouse liver\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis combined with in vitro and in vivo functional validation, mechanistic link between dimerization and activity established\",\n      \"pmids\": [\"8999814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The 65-kDa complementing activity (later identified as ACF) binds specifically to the mooring sequence of apoB mRNA (not antisense or mooring-sequence mutants) in the absence of apobec-1, and also interacts with apobec-1, supporting a model where it is the RNA-binding subunit of the holoenzyme.\",\n      \"method\": \"RNA affinity chromatography, UV cross-linking, far-Western analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical purification with multiple orthogonal methods (affinity chromatography, UV cross-linking, far-Western), rigorous mooring-sequence mutant controls\",\n      \"pmids\": [\"9671452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"APOBEC1 complementation factor (ACF), a 64.3-kDa protein with three RNA recognition motifs, is identified and purified; ACF and apobec-1 constitute the minimal protein requirements for apoB mRNA editing in vitro. ACF binds apoB mRNA via the mooring sequence (UV cross-linking, immunoprecipitation), and ACF-apobec-1 complex forms in transfected cells. Immunodepletion of ACF from liver extracts abolishes editing.\",\n      \"method\": \"Protein purification, peptide sequencing, molecular cloning, UV cross-linking, immunoprecipitation, co-immunoprecipitation, immunodepletion, in vitro editing reconstitution\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — purification to homogeneity, in vitro reconstitution with minimal components, multiple orthogonal methods, immunodepletion rescue\",\n      \"pmids\": [\"10669759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"APOBEC1 binds AU-rich sequences with consensus UUUN[A/U]U (Kd ~50 nM for high-affinity sites, ~435 nM for apoB RNA); binding of APOBEC1 to this consensus in c-myc 3'UTR stabilizes c-myc mRNA (half-life increased from 90 to 240 min), an effect abolished by RNA-binding–deficient APOBEC1 mutants.\",\n      \"method\": \"Filter binding assays, circular permutation analysis, RNA secondary structure prediction, mRNA half-life assay with actinomycin D, transfection of APOBEC1 expression mutants\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro binding assays with Kd measurements plus in vivo mRNA stability assay with mutant controls, multiple orthogonal methods\",\n      \"pmids\": [\"10688645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"GRY-RBP, an RNA-binding protein with ~50% homology to ACF, is a component of the apoB mRNA editosome; it binds both ACF and apobec-1, binds apoB RNA, and inhibits C-to-U editing by sequestering ACF (competitive inhibition rescued by excess ACF). Antisense knockdown of GRY-RBP in hepatoma cells increases apoB RNA editing.\",\n      \"method\": \"Yeast two-hybrid, two-hybrid screen, peptide sequencing of active fraction, recombinant protein binding assays, immunodepletion, antisense knockdown, co-localization in transfected cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple biochemical methods including pulldown, functional reconstitution, antisense knockdown, and co-localization\",\n      \"pmids\": [\"11134005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CUGBP2 is a component of the apoB mRNA editing holoenzyme; it co-fractionates with ACF, immunodepletion of CUGBP2 co-precipitates ACF, CUGBP2 binds apoB RNA at an AU-rich sequence upstream of the edited cytidine, and addition of recombinant CUGBP2 dose-dependently inhibits C-to-U editing rescued by apobec-1 or ACF.\",\n      \"method\": \"Co-fractionation, immunodepletion, co-immunoprecipitation, UV cross-linking, in vitro editing reconstitution, antisense knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple biochemical and cell-based assays, antisense knockdown with editing readout, inhibitor rescue experiment\",\n      \"pmids\": [\"11577082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ARCD-1, an apobec-1 homologue, has cytidine deaminase and apoB RNA binding activity but cannot mediate C-to-U RNA editing; it interacts with and heterodimerizes with apobec-1 and ACF, acting as a dominant negative inhibitor of apoB mRNA editing.\",\n      \"method\": \"Recombinant protein activity assays, heterodimerization immunoprecipitation, in vitro and in vivo editing assays, subcellular localization\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and cell-based assays, single lab, multiple methods but ARCD-1 is a paralog, not APOBEC1 itself; mechanistically informs APOBEC1 dimerization\",\n      \"pmids\": [\"11698249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ABBP-2, a DnaJ/Hsp40 homologue identified by yeast two-hybrid, binds apobec-1 via its J domain and G/F domain; knockdown of ABBP-2 inhibits apoB mRNA editing; editing activity of tissue extracts requires Hsp70/ABBP-2 and is abolished by removal of endogenous ATP (which disrupts ABBP-2–Hsp70 interaction), implicating a chaperone function in editosome assembly.\",\n      \"method\": \"Yeast two-hybrid, domain deletion mapping, transfection GFP fusion, antisense knockdown in cells, in vitro editing assay with ATP depletion, Hsp70 co-IP\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus in vitro functional assays and cell-based knockdown, single lab\",\n      \"pmids\": [\"11584023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ACF domains required for RNA binding and apobec-1 interaction were mapped: the N-terminal RRMs (especially RRM1 and RRM2) together with the pre-RRM region are necessary for apoB mRNA binding and complementing activity; the auxiliary domain RG-rich region is required for RNA binding and apobec-1 interaction; the RRMs are also required for apobec-1 interaction.\",\n      \"method\": \"Deletion and point mutagenesis of ACF, in vitro binding assays (Kd measurements), in vitro editing complementation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis with quantitative binding assays and functional reconstitution, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"11571303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ACF is a nuclear protein that upon co-transfection with apobec-1 promotes nuclear co-localization of apobec-1 (which is otherwise predominantly cytoplasmic); protein–protein interaction between ACF and apobec-1 is required for nuclear import of apobec-1; ACF NLS mutants that cannot interact with apobec-1 leave apobec-1 in the cytoplasm.\",\n      \"method\": \"Transfection of ACF/APOBEC1 constructs, immunofluorescence co-localization, deletion/mutation of NLS\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based localization with mutant controls, single lab\",\n      \"pmids\": [\"11571303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ACF binds single-stranded but not double-stranded apoB mRNA with high affinity; all three RRMs contribute to RNA binding; point mutations in RRM1 or RRM2 decrease Kd for apoB mRNA by two orders of magnitude; the pre-RRM region is required for complementing activity and RNA binding but not for apobec-1 interaction.\",\n      \"method\": \"Deletion mutagenesis, point mutagenesis, binding assays with Kd measurements, in vitro editing complementation assay\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis with quantitative binding measurements and reconstitution, single lab\",\n      \"pmids\": [\"11871661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"APOBEC1 and its homologs APOBEC3C and APOBEC3G exhibit DNA mutator activity in E. coli through cytosine deamination (dC→dU), with each protein showing distinct local target sequence specificity.\",\n      \"method\": \"E. coli rifampicin-resistance mutation assay, expression of APOBEC1 and homologs in bacteria\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional bacterial assay with defined readout, single lab, replicated for multiple family members\",\n      \"pmids\": [\"12453430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"APOBEC1 deaminates cytosine to uracil in single-stranded DNA in vitro (using partially purified APOBEC1 from E. coli extracts); activity is specific for ssDNA (not dsDNA) and exhibits local sequence context dependence.\",\n      \"method\": \"In vitro biochemical deamination assay using partially purified recombinant APOBEC1, substrate specificity characterization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro enzyme assay with purified protein, ssDNA vs dsDNA specificity established biochemically\",\n      \"pmids\": [\"12697753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ACF localizes to the nucleus via a novel 41-residue nuclear localization signal (ANS) in its auxiliary domain; ACF is a nucleocytoplasmic shuttling protein (confirmed by heterokaryon assay); nuclear accumulation is CRM1-dependent for export and transportin-2–dependent for import; transportin 2 binds directly to the ANS motif.\",\n      \"method\": \"GFP/β-galactosidase chimera nuclear localization assay, actinomycin D treatment, leptomycin B CRM1 inhibition, heterokaryon assay, co-immunoprecipitation with transportin 2, confocal microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell-based assays with pharmacological and genetic controls, co-IP of binding partner; concerns ACF not APOBEC1 directly but relevant to APOBEC1 nuclear import\",\n      \"pmids\": [\"12896982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Crystal structure of yeast CDD1, an APOBEC1 ortholog, at 2.0-Å resolution reveals the fold; comparative modeling of APOBEC1 indicates dimerization and trans-acting loops contributing to active site formation; a central active site 'flap' accommodates large substrates (RNA or ssDNA), explaining equal likelihood of APOBEC1 binding ssDNA or RNA.\",\n      \"method\": \"X-ray crystallography of CDD1, comparative structural modeling of APOBEC1 and AID\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure of ortholog plus comparative modeling; APOBEC1 structure itself not directly solved in this study\",\n      \"pmids\": [\"15148397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Purified APOBEC1 apoenzyme has intrinsic residual editing activity on a minimal apoB mRNA substrate without auxiliary factors; ACF broadens the temperature range and lowers the optimal temperature for editing activity, consistent with ACF promoting a conformational transition in the RNA substrate.\",\n      \"method\": \"Expression and purification to homogeneity of APOBEC1, in vitro editing kinetics assay with and without ACF, factorial and response surface experimental design\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — purified protein reconstitution with kinetic characterization and auxiliary factor comparison, single lab but rigorous biochemistry\",\n      \"pmids\": [\"15273326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Apobec-1 binds to AU-rich sequences in the COX-2 mRNA 3'UTR (first 60 nt) via EMSA and UV cross-linking, stabilizing COX-2 mRNA; apobec-1-knockout mice show reduced COX-2 induction and intestinal stem cell survival after gamma-irradiation, an effect mediated through COX-2/prostaglandin E2.\",\n      \"method\": \"EMSA, UV cross-linking, mRNA half-life assay with chimeric luciferase-COX-2 3'UTR reporter, apobec-1 knockout mice with irradiation model, real-time PCR, Western blot\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro binding assays plus in vivo knockout phenotype with molecular mechanism, multiple orthogonal methods\",\n      \"pmids\": [\"15480992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NMR structure of the 31-nt apoB mRNA stem-loop shows the edited cytidine (C6666) is stacked in a loop and inaccessible to APOBEC1 alone; APOBEC1 does not specifically bind apoB mRNA by itself but requires ACF, which recognizes the flexible mooring sequence and melts the stem-loop to expose C6666 to APOBEC1.\",\n      \"method\": \"NMR structure determination of apoB mRNA stem-loop, RNA binding assays with APOBEC1 and ACF\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure plus functional RNA binding analysis, provides mechanistic explanation for ACF requirement\",\n      \"pmids\": [\"15659357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"APOBEC1 and AID are nucleo-cytoplasmic trafficking proteins, whereas APOBEC3G is strongly retained in the cytoplasm through mechanisms involving both N- and C-terminal regions.\",\n      \"method\": \"Subcellular fractionation, nucleo-cytoplasmic shuttling assays in cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based localization assays, single lab, direct comparison of family members\",\n      \"pmids\": [\"16999936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ACF phosphorylation (on serine residues, predominantly by protein phosphatase I-sensitive kinase) regulates apoB mRNA editing: phosphorylated ACF is restricted to nuclei and co-sediments with editing-competent 27S complexes; alkaline phosphatase treatment reduces APOBEC-1 co-immunoprecipitation with ACF and inhibits editing; ethanol stimulates both ACF phosphorylation and editing.\",\n      \"method\": \"Co-immunoprecipitation, alkaline phosphatase treatment of nuclear extracts, glycerol gradient sedimentation, two-dimensional phosphoamino acid analysis, protein phosphatase inhibitor treatment in primary hepatocytes\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple biochemical methods linking ACF phosphorylation to editosome assembly and APOBEC1 interaction, in vitro and cell-based evidence\",\n      \"pmids\": [\"16820530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ACF phosphorylation at S154 and S368 by PKC regulates apoB mRNA editing; PKC activation stimulates editing and ACF phosphorylation; S154A/S368A mutations inhibit ethanol-stimulated editing; S154D/S368D phosphomimetics stimulate editing to levels comparable to ethanol treatment.\",\n      \"method\": \"PKC/PKA pharmacological activation in primary hepatocytes, in vitro phosphorylation of purified ACF by PKC, site-directed mutagenesis (alanine/aspartate substitutions), in vitro editing assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro phosphorylation with purified protein combined with mutagenesis and cell-based functional assay, single lab\",\n      \"pmids\": [\"17229474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Deletion of apobec-1 in Apc(min/+) mice dramatically reduces intestinal adenoma formation, associated with increased apoptosis, reduced proliferation, reduced COX-2 mRNA (~2-fold vs. adenomas), and reduced expression of other AU-rich mRNA targets (EGFR, PPARδ, EP4, c-myc) containing the apobec-1 consensus binding site. Adenoviral apobec-1 in HCA-7 cells dose-dependently increases COX-2 protein and stabilizes COX-2 mRNA.\",\n      \"method\": \"Genetic epistasis (compound Apc(min/+) apobec-1(-/-) mice), intestinal adenoma counting, apoptosis and proliferation assays, mRNA quantification, adenoviral apobec-1 delivery in cancer cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with multiple molecular readouts plus cell-based confirmation, multiple orthogonal methods\",\n      \"pmids\": [\"17875695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"APOBEC1 binds to AU-rich regions of the Cyp7a1 mRNA 3'UTR containing the UUUN(A/U)U consensus, as shown by UV cross-linking and in vivo RNA co-immunoprecipitation; Apobec-1-knockout mice show decreased Cyp7a1 mRNA and protein (without changes in transcription), increased gallstone susceptibility, and adenoviral Apobec-1 rescue restores Cyp7a1 expression.\",\n      \"method\": \"UV cross-linking to recombinant APOBEC1, in vivo RNA co-immunoprecipitation, Cyp7a1 transcription run-on, adenoviral rescue in knockout mice, lithogenic diet model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro binding plus in vivo RNA co-IP plus knockout/rescue experiment, multiple orthogonal methods\",\n      \"pmids\": [\"19386592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"APOBEC1 edits multiple mRNA targets (32 validated) located in AU-rich segments of transcript 3'UTRs, identified by transcriptome-wide comparative RNA-Seq of APOBEC1-expressing vs. non-expressing conditions; editing sites share characteristic sequence features.\",\n      \"method\": \"Transcriptome-wide comparative RNA-Seq (APOBEC1+ vs. control), Sanger sequence validation of editing sites\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased genome-wide approach with validation, dramatically expanded known substrate repertoire\",\n      \"pmids\": [\"21258325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"APOBEC1 (A1) restricts LINE-1 and LTR retrotransposons (IAP, MusD) in cell-culture retrotransposition assays; anti-L1 activity is deamination-independent, whereas inhibition of LTR-retrotransposons requires deaminase activity; restriction is not affected by subcellular localization.\",\n      \"method\": \"Cell culture-based retrotransposition assays, deaminase-inactive mutant controls, subcellular localization experiments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based functional assay with catalytic mutant controls distinguishing two mechanisms, single lab\",\n      \"pmids\": [\"21398638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RBM47 is a novel RNA-binding protein that interacts with APOBEC1 and A1CF; RBM47 can substitute for A1CF in APOBEC1-mediated C-to-U RNA editing in vitro and is necessary and sufficient for APOBEC1-mediated editing; Rbm47-deficient mice exhibit impaired RNA editing.\",\n      \"method\": \"Co-immunoprecipitation of RBM47 with APOBEC1 and A1CF, in vitro editing assay with RBM47, Rbm47 knockout mice\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — protein interaction assays plus in vitro reconstitution plus in vivo knockout, multiple orthogonal methods\",\n      \"pmids\": [\"24916387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Genome-wide deep sequencing of intestinal and hepatic RNA from wild-type and Apobec-1-deficient mice reveals 56 novel editing sites in 54 intestinal mRNAs and 22 sites in 17 liver mRNAs (all in 3'UTRs); editing leads to corresponding changes in intestinal mRNA and protein levels for 11 genes; Apobec-1 adenoviral or transgenic rescue restores editing; cell-free extracts from wild-type but not Apobec-1(-/-) mice support editing.\",\n      \"method\": \"Deep sequencing (RNA-Seq), Sanger-sequence validation, tissue-specific Apobec-1 adenoviral and transgenic overexpression rescue, cell-free editing assays, polysome profiling\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide approach with knockout/rescue validation and cell-free mechanistic confirmation, multiple orthogonal methods\",\n      \"pmids\": [\"24946870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A1CF (APOBEC1 complementation factor) is dispensable for C-to-U RNA editing in vivo under normal physiological conditions: A1cf conditional null mice are viable and fertile, with no changes in editing efficiency at multiple targets including ApoB in small intestine and liver.\",\n      \"method\": \"Conditional A1cf knockout mice, quantitative C-to-U RNA editing at multiple targets in small intestine and liver\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with comprehensive editing analysis, contradicts earlier in vitro models, replicated by independent group (PMID:30309881)\",\n      \"pmids\": [\"28069890\", \"30309881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"APOBEC1-mediated RNA editing occurs in microglia and is required for maintaining their resting state; mice lacking APOBEC1 editing function in microglia display progressive age-related neurodegeneration, activated microglial clustering, aberrant myelination, increased inflammation, and lysosomal anomalies with behavioral and motor deficiencies.\",\n      \"method\": \"APOBEC1 RNA editing analysis in microglia, conditional APOBEC1 knockout mice, histopathological and behavioral phenotyping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo knockout with multiple phenotypic readouts but mechanism linking specific editing targets to phenotype not fully defined from abstract\",\n      \"pmids\": [\"29167375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A1CF and RBM47 each function independently but interact in a tissue-specific manner to regulate APOBEC1-dependent C-to-U RNA editing; double knockout of A1cf and Rbm47 in liver virtually eliminates apoB RNA editing and reduces most other targets; intestinal double knockout further reduces editing beyond single Rbm47 knockout; forced A1CF expression alone does not restore editing in double knockouts.\",\n      \"method\": \"Tissue-specific single and double conditional knockouts of A1cf and Rbm47, adenoviral APOBEC1 rescue, RNA-Seq, quantitative editing analysis\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with tissue-specific double knockouts and rescue experiments, comprehensive editing analysis\",\n      \"pmids\": [\"30309881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"APOBEC1-RBM47 and APOBEC1-A1CF complexes reconstituted in HEK293T cells show differential RNA editing activity: A1CF and RBM47 differ in their selectivity for specific RNA targets; human vs. mouse versions of cofactors differ in activity; minimal domain of RBM47 required for activity was defined.\",\n      \"method\": \"Reconstitution of APOBEC1 with either cofactor in HEK293T cells, cell-based fluorescent editing reporter assay, domain deletion analysis of RBM47\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution in defined cell system with quantitative editing assay and domain mapping, single lab\",\n      \"pmids\": [\"30844405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structure of APOBEC1 reveals a typical APOBEC deaminase core plus a unique well-folded hydrophobic C-terminal domain (A1HD) that forms a stable dimer via hydrophobic interactions creating a four-stranded β-sheet positively charged surface; structure-guided mutagenesis shows A1HD directs RNA substrate and cofactor interactions.\",\n      \"method\": \"X-ray crystallography of APOBEC1, structure-guided mutagenesis, biochemical characterization of RNA/DNA substrate selectivity\",\n      \"journal\": \"NAR cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus functional mutagenesis, direct structural determination of APOBEC1 itself\",\n      \"pmids\": [\"33094286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"APOBEC1 cytosine deaminase activity on ssDNA is suppressed by replication protein A (RPA) competition for ssDNA; APOBEC1 cannot efficiently compete with RPA in vitro, correlating with low levels of genomic DNA damage (γH2AX foci) in lung cancer cells, suggesting RPA acts as a defense against APOBEC1 off-target deamination.\",\n      \"method\": \"In vitro ssDNA deamination assay with RPA competition, γH2AX foci assay in lung cancer cell line\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro biochemical assay plus cell-based DNA damage measurement, single lab, mechanistic link between RPA competition and genomic protection established\",\n      \"pmids\": [\"33330905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"APOBEC1 dimerization requires the C-terminal region; N-terminal deletions up to residue A117 do not impair dimerization, while C-terminal deletions reduce it; basic amino acid clusters R15R16R17 and R33K34 are essential for apoB mRNA editing; residues L182, I185, L189 and a β-turn (P190/P191) in the leucine-rich C-terminal region are required for normal editing function.\",\n      \"method\": \"Systematic targeted mutagenesis, in vitro apoB mRNA editing assay, immunoprecipitation dimerization assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis with in vitro reconstitution and dimerization assays, comprehensive structure-function analysis\",\n      \"pmids\": [\"10191286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In yeast expressing APOBEC-1, apoB mRNA editing occurs preferentially in the nucleus; cis-acting sequence requirements and intracellular distribution of APOBEC-1 in yeast are similar to those in mammalian cells, suggesting auxiliary protein functions required for editosome assembly are conserved in yeast.\",\n      \"method\": \"Yeast expression system for APOBEC-1, apoB mRNA editing assay, intracellular localization\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — heterologous cell system reconstitution with editing activity and localization, single lab\",\n      \"pmids\": [\"10606639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"APOBEC1 expression in chicken DT40 cells increases inactivation of a stably inserted reporter gene and increases imatinib-resistant clones in a human CML model through induction of mutations in BCR-ABL1, demonstrating APOBEC1 acts as a DNA mutator in vertebrate cells.\",\n      \"method\": \"Reporter gene inactivation assay in DT40 cells, imatinib-resistance mutation induction assay in human CML cells, BCR-ABL1 sequencing\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based functional assay with molecular sequencing readout, single lab\",\n      \"pmids\": [\"25085003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"hnRNPQ isoform 6 (hnRNPQ6) is required for efficient interaction of APOBEC1 with IL-8 mRNA in HuH7.5 cells; APOBEC1 binding to AU-rich elements in IL-8 3'UTR extends mRNA half-life and increases IL-8 production in a cell-type-specific and hnRNPQ6-dependent manner.\",\n      \"method\": \"FLAG-tagged APOBEC1 immunoprecipitation followed by microarray (RNA-IP), siRNA screen, yeast two-hybrid, reporter assay with IL-8 3'UTR-luciferase, mRNA half-life measurement, overexpression of hnRNPQ isoforms\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-IP, siRNA screen, reporter assay and mRNA stability in combination, single lab\",\n      \"pmids\": [\"25100733\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOBEC1 is the catalytic cytidine deaminase subunit of the apoB mRNA editing complex, acting within a multiprotein holoenzyme (minimally requiring RBM47, and optionally A1CF, as RNA-binding cofactors) to perform site-specific C-to-U deamination of apoB mRNA at C6666 in the intestine/liver; it functions as a homodimer whose dimerization, zinc-coordinating residues (His61, Cys93, Cys96), catalytic Glu63, and C-terminal hydrophobic domain are all required for activity; beyond apoB mRNA, APOBEC1 binds AU-rich 3'UTR sequences (consensus UUUN[A/U]U) in dozens of mRNA targets to stabilize them (e.g., COX-2, c-myc, Cyp7a1, IL-8); it can also deaminate cytosines in single-stranded DNA (suppressed by RPA competition) and restrict retroelements via both deaminase-dependent and -independent mechanisms; its nuclear activity is regulated by ACF/RBM47 cofactor phosphorylation and nucleo-cytoplasmic shuttling, while microglia-specific APOBEC1-mediated RNA editing is required for maintaining CNS homeostasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"APOBEC1 is the catalytic zinc-dependent cytidine deaminase that performs site-specific C-to-U editing of apoB mRNA at the canonical site, and its targeted disruption in mice abolishes all apoB mRNA editing and eliminates serum apoB48, establishing it as the essential and non-redundant catalytic component of the editing apparatus [#0, #2]. Its activity depends on zinc-coordinating residues (His61, Cys93, Cys96) and catalytic Glu63, while a leucine-rich C-terminal region and basic N-terminal clusters are additionally required for RNA editing; the enzyme functions as a homodimer, and dimerization-competent inactive mutants act as dominant negatives [#0, #39, #6]. The crystal structure of APOBEC1 shows a deaminase core plus a unique hydrophobic C-terminal domain (A1HD) that mediates stable dimerization and directs RNA substrate and cofactor interactions [#37]. APOBEC1 alone cannot specifically bind the apoB stem-loop, in which the target cytidine C6666 is sequestered; an RNA-binding cofactor recognizes the mooring sequence and melts the stem-loop to present the substrate [#23]. Two cofactors fulfill this role: A1CF (ACF) was identified biochemically as the minimal complementing factor in vitro [#8], but genetic studies showed RBM47 is necessary and sufficient for editing and that A1CF is dispensable in vivo, with the two acting tissue-specifically and redundantly such that combined loss eliminates editing [#31, #33, #35]. Beyond mRNA editing, APOBEC1 binds AU-rich 3'UTR sequences with consensus UUUN[A/U]U to stabilize target mRNAs including c-myc, COX-2, and Cyp7a1, linking it to intestinal stem cell survival, adenoma formation, and bile acid/gallstone physiology [#9, #22, #27, #28]. Transcriptome-wide sequencing established dozens of physiological 3'UTR editing targets in intestine and liver [#29, #32]. APOBEC1 also deaminates cytosines in single-stranded DNA, acting as a vertebrate DNA mutator whose off-target activity is restrained by RPA competition, and it restricts LINE-1 and LTR retrotransposons through both deaminase-dependent and -independent mechanisms [#18, #41, #38, #30]. Microglial APOBEC1-mediated RNA editing is required to maintain CNS homeostasis, with its loss causing progressive neurodegeneration [#34].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined which residues and domains of APOBEC1 underlie catalysis versus RNA recognition, separating the deaminase chemistry from editing-specific requirements.\",\n      \"evidence\": \"Site-directed mutagenesis of GST-APOBEC1 with in vitro deaminase, editing, and UV cross-linking RNA-binding assays in McA7777 cells\",\n      \"pmids\": [\"7782343\", \"7782342\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether APOBEC1 acts alone or requires cofactors for editing\", \"Structural basis of domain functions not resolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Established APOBEC1 as the essential, non-redundant catalytic component of apoB mRNA editing in vivo.\",\n      \"evidence\": \"Targeted apobec-1 knockout mice with apoB mRNA editing analysis and serum apoB48 Western blot\",\n      \"pmids\": [\"8621694\", \"8824235\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the auxiliary factors required for editing\", \"Overexpression caused promiscuous hyperediting, implying tight regulation not yet explained\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrated that APOBEC1 alone is insufficient and requires a directly-interacting auxiliary complementing protein for editing.\",\n      \"evidence\": \"APOBEC1 affinity chromatography, depletion/reconstitution of in vitro editing, glycerol gradient sedimentation\",\n      \"pmids\": [\"8910449\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the 65 kDa complementing protein not yet determined\", \"Stoichiometry of the holoenzyme unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Mapped the structural determinants of APOBEC1 homodimerization to the C-terminal region and identified basic clusters required for editing.\",\n      \"evidence\": \"Systematic targeted mutagenesis with in vitro editing and immunoprecipitation dimerization assays\",\n      \"pmids\": [\"10191286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of the dimer interface not resolved at this stage\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified and purified ACF as the RNA-binding subunit, defining the minimal two-protein editing holoenzyme.\",\n      \"evidence\": \"Protein purification, peptide sequencing, cloning, UV cross-linking, co-IP, immunodepletion and in vitro reconstitution\",\n      \"pmids\": [\"10669759\", \"9671452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test whether ACF is the sole physiological cofactor in vivo\", \"Mechanism of mooring-sequence recognition not structurally defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed a deaminase-independent role: APOBEC1 binds AU-rich 3'UTR consensus sequences to stabilize target mRNAs such as c-myc.\",\n      \"evidence\": \"Filter binding with Kd measurements, circular permutation, mRNA half-life assay with mutant controls\",\n      \"pmids\": [\"10688645\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of mRNA stabilization not yet shown in vivo at this point\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Characterized additional editosome-associated RNA-binding proteins and their regulatory roles in editing.\",\n      \"evidence\": \"Yeast two-hybrid, immunodepletion, antisense knockdown, in vitro editing reconstitution for GRY-RBP, CUGBP2, ABBP-1, ABBP-2, and the dominant-negative paralog ARCD-1\",\n      \"pmids\": [\"11134005\", \"11577082\", \"8999813\", \"11584023\", \"11698249\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo requirement of these accessory factors not established by knockout\", \"Most identified by single-lab two-hybrid plus in vitro assays\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed that ACF mediates nuclear import of cytoplasmic APOBEC1, coupling cofactor binding to subcellular localization.\",\n      \"evidence\": \"Co-transfection immunofluorescence with ACF NLS mutants and domain mapping\",\n      \"pmids\": [\"11571303\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab cell-based localization\", \"Did not define import machinery used\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Provided the structural rationale for the cofactor requirement by showing the target cytidine is sequestered in the apoB stem-loop and exposed only via ACF-mediated melting.\",\n      \"evidence\": \"NMR structure of the 31-nt apoB stem-loop and RNA binding assays with APOBEC1 and ACF\",\n      \"pmids\": [\"15659357\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-structure of the assembled holoenzyme on RNA\", \"Apoenzyme retains residual activity, complicating a strict obligate-cofactor model\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked cofactor phosphorylation to editosome assembly, establishing a signaling-responsive regulatory layer.\",\n      \"evidence\": \"Co-IP, alkaline phosphatase treatment, glycerol gradient sedimentation, PKC phosphorylation and S154/S368 phosphomimetic mutagenesis in hepatocytes\",\n      \"pmids\": [\"16820530\", \"17229474\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether APOBEC1 itself is phosphorylated not addressed\", \"Physiological signals beyond ethanol/PKC not delineated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Extended the AU-rich-binding/mRNA-stabilization function to physiology, connecting APOBEC1 to COX-2 stabilization and intestinal stem cell survival.\",\n      \"evidence\": \"EMSA, UV cross-linking, luciferase-3'UTR reporter half-life, and apobec-1 knockout irradiation mouse model\",\n      \"pmids\": [\"15480992\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not distinguish stabilization from editing for the same targets in vivo\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established a tumor-promoting role through stabilization of AU-rich oncogenic mRNAs in the intestine.\",\n      \"evidence\": \"Compound Apc(min/+) apobec-1(-/-) genetic epistasis, adenoma counting, mRNA quantification, adenoviral rescue in cancer cells\",\n      \"pmids\": [\"17875695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of editing vs. stabilization to tumorigenesis not separated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated post-transcriptional control of bile acid metabolism via APOBEC1 binding and stabilization of Cyp7a1 mRNA.\",\n      \"evidence\": \"UV cross-linking, in vivo RNA co-IP, transcription run-on, adenoviral rescue and lithogenic diet in knockout mice\",\n      \"pmids\": [\"19386592\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactor dependence of Cyp7a1 binding not defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a genome-wide repertoire of APOBEC1 C-to-U editing targets concentrated in AU-rich 3'UTRs.\",\n      \"evidence\": \"Transcriptome-wide comparative RNA-Seq with Sanger validation; cell-based and in vivo follow-up\",\n      \"pmids\": [\"21258325\", \"24946870\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences for most edited transcripts not characterized\", \"Cofactor used per target not assigned\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified RBM47 as a cofactor that is necessary and sufficient for editing in vivo, reframing the ACF-centric model.\",\n      \"evidence\": \"Co-IP with APOBEC1 and A1CF, in vitro reconstitution, and Rbm47 knockout mice\",\n      \"pmids\": [\"24916387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific division of labor between cofactors not yet resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Characterized APOBEC1 as a vertebrate ssDNA DNA mutator capable of inducing drug-resistance mutations.\",\n      \"evidence\": \"Reporter inactivation in DT40 cells and imatinib-resistance/BCR-ABL1 mutation assay in CML cells; in vitro ssDNA deamination\",\n      \"pmids\": [\"25085003\", \"12697753\", \"12453430\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genomic mutagenesis significance in normal tissues unclear\", \"Cell-based assays from single labs\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed A1CF is dispensable for physiological editing in vivo and revealed an APOBEC1 RNA-editing requirement in microglia for CNS homeostasis.\",\n      \"evidence\": \"A1cf conditional knockout editing analysis; microglia-specific APOBEC1 editing loss with neuropathological and behavioral phenotyping\",\n      \"pmids\": [\"28069890\", \"30309881\", \"29167375\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific microglial editing targets driving neurodegeneration not identified\", \"Mechanism linking editing to resting-state maintenance unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved cofactor redundancy by showing A1CF and RBM47 act tissue-specifically with combined loss eliminating editing.\",\n      \"evidence\": \"Tissue-specific single and double conditional A1cf/Rbm47 knockouts with adenoviral rescue and RNA-Seq editing analysis\",\n      \"pmids\": [\"30309881\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of which cofactor selects which target only partly defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided the APOBEC1 crystal structure, defining the A1HD dimerization domain that directs RNA and cofactor interactions.\",\n      \"evidence\": \"X-ray crystallography of APOBEC1 with structure-guided mutagenesis and substrate selectivity assays\",\n      \"pmids\": [\"33094286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of APOBEC1 bound to cofactor or RNA substrate\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed RPA competition for ssDNA limits APOBEC1 off-target genomic deamination, defining a cellular defense against its mutator activity.\",\n      \"evidence\": \"In vitro ssDNA deamination with RPA competition and γH2AX foci in lung cancer cells\",\n      \"pmids\": [\"33330905\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of RPA protection not established\", \"Single-lab study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how cofactor identity (A1CF vs RBM47) and tissue context determine target selection, and which specific edited transcripts mediate the microglial/CNS homeostasis function.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No holoenzyme-on-RNA structure\", \"Target-specificity rules of each cofactor undefined\", \"Causal microglial editing targets unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 2, 21, 29, 32]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [18, 17, 41, 38]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [1, 9, 23, 28]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 18]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [9, 22, 28]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [15, 24]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [15, 40, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [2, 8, 29, 32]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [28, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [27, 41]}\n    ],\n    \"complexes\": [\"apoB mRNA editing holoenzyme (editosome)\"],\n    \"partners\": [\"A1CF\", \"RBM47\", \"GRY-RBP\", \"CUGBP2\", \"hnRNPQ\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}